GlaxoSmithKline (GSK) PT Raised to $45 at Argus
Tweet Send to a Friend
Argus analyst John Eade raised the price target on GlaxoSmithKline (NYSE: GSK) to $45.00 while maintaining a Buy rating.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
